Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
根据最新的财务报表(Form-10K),Apimeds Pharmaceuticals US Inc 的总资产为 $0,净损失为 $0
APUS 的关键财务比率是什么?
Apimeds Pharmaceuticals US Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Apimeds Pharmaceuticals US Inc 的收入按细分市场或地理位置如何划分?
Apimeds Pharmaceuticals US Inc 最大收入来源是 Aquaculture and Agriculture,在最近的收益报告中收入为 13,169,135。就地区而言, Malaysia 是 Apimeds Pharmaceuticals US Inc 的主要市场,收入为 13,178,101。
Apimeds Pharmaceuticals US Inc 是否盈利?
不,根据最新的财务报表,Apimeds Pharmaceuticals US Inc 的净损失为 $0